Collagen derived serum markers in carcinoma of the prostate.

Three new collagen markers deriving from the collagenous matrix, e.g. carboxyterminal propeptide of type I procollagen (PICP), carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP), and aminoterminal propeptide of type III procollagen (PIIINP) were used for the diagnose of prostatic bone metastases. Blood samples were obtained prior to biopsy or TURP. Serum PICP, PIIINP and ICTP were measured with commercial available RIAs and PSA by IRMA. Serum PSA was increased in patients with local prostatic cancer compared with patients with hyperplasia (p < 0.05). The level of PIIINP, ICTP, and PICP did not differ between these two groups. In patients with metastatic prostatic cancer all five markers were increased compared to the level measured in patients with localized cancer (p < 0.0001). All variables showed a significant positive relationship with alkaline phosphatase. The sensitivity ranged from 0.53 to 0.62 and specificity from 0.91 to 0.95. The sensitivity for alkaline phosphatase and PSA was 0.69 and 0.66 and specificity 0.91 and 0.68, respectively.

[1]  J. Risteli,et al.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. , 1993, Clinical chemistry.

[2]  J. Oesterling,et al.  The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.

[3]  T. Tammela,et al.  Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. , 1993, European journal of cancer.

[4]  E. Cooper,et al.  Tumor markers in prostate cancer , 1992, Cancer.

[5]  H. Scher,et al.  Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. , 1992, The Journal of urology.

[6]  Y. Arai,et al.  Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? , 1992, The Prostate.

[7]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[8]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[9]  C. Christiansen,et al.  The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. , 1991, Metabolism: clinical and experimental.

[10]  R. Sylvester,et al.  Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer , 1990, Cancer.

[11]  P. Robinson,et al.  Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer , 1990, Cancer.

[12]  J. Risteli,et al.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.

[13]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. , 1989, The Journal of urology.

[14]  R. Sylvester,et al.  Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. , 1989, The Journal of urology.

[15]  M. Caleffi,et al.  Osteocalcin: a potential marker of metastatic bone disease and response to treatment. , 1988, European journal of cancer & clinical oncology.

[16]  J. Risteli,et al.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. , 1988, Clinical chemistry.

[17]  J. Grob,et al.  Quantitative bone scintigraphy: usefulness in the survey of patients treated for bone metastasis of prostatic cancer. , 1988, European urology.

[18]  Sogani Pc,et al.  Treatment of advanced prostatic cancer. , 1987 .

[19]  S. Suciu,et al.  Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762. , 1984, British journal of urology.

[20]  M. Soloway,et al.  Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. , 1983, The Journal of urology.

[21]  M. Menon,et al.  Tumor Markers in Prostatic Cancer , 1983 .

[22]  H. Pendergrass,et al.  Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. , 1976, Radiology.